Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine 60 mg vs 120 mg in Hospitalized Severe Depression
NCT02229825Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2007
- Primary completion
- Aug 2008
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of duloxetine in major depressive disorder (MDD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 4 weeks. Started Feb 2007; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02229825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229825.